194 related articles for article (PubMed ID: 32039450)
1. Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin.
Wang X; Liu Y; Qin Q; Zheng T
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32039450
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma.
Zheng W; Yao M; Sai W; Qian Q; Pan L; Qiu L; Huang J; Wu W; Yao D
Tumour Biol; 2016 Jan; 37(1):999-1008. PubMed ID: 26264614
[TBL] [Abstract][Full Text] [Related]
3. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
[TBL] [Abstract][Full Text] [Related]
4. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
5. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
6. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
7. [Down-regulated clusterin expression enhances sensitivity of hepatoma cells to anti-cancer drugs].
Zheng WJ; Sai WL; Yao M; Cai Y; Pan LH; Gu JJ; Wu W; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):844-8. PubMed ID: 26743245
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors.
Gao B; Yang FM; Yu ZT; Li R; Xie F; Chen J; Luo HJ; Zhang JC
Int J Clin Exp Pathol; 2015; 8(6):6995-7001. PubMed ID: 26261589
[TBL] [Abstract][Full Text] [Related]
9. Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells.
Zheng W; Sai W; Yao M; Gu H; Yao Y; Qian Q; Yao D
Tumour Biol; 2015 May; 36(5):3995-4003. PubMed ID: 25600802
[TBL] [Abstract][Full Text] [Related]
10. The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.
Patarat R; Riku S; Kunadirek P; Chuaypen N; Tangkijvanich P; Mutirangura A; Puttipanyalears C
Sci Rep; 2021 Jul; 11(1):14838. PubMed ID: 34290294
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.
Zeng YL; Guo ZY; Su HZ; Zhong FD; Jiang KQ; Yuan GD
World J Gastroenterol; 2019 Dec; 25(48):6902-6915. PubMed ID: 31908394
[TBL] [Abstract][Full Text] [Related]
12. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
Liao X; Bu Y; Jiang S; Chang F; Jia F; Xiao X; Song G; Zhang M; Ning P; Jia Q
Hepatol Int; 2019 Jul; 13(4):440-453. PubMed ID: 31250351
[TBL] [Abstract][Full Text] [Related]
13. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
[TBL] [Abstract][Full Text] [Related]
14. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.
Yin X; Zheng SS; Zhang L; Xie XY; Wang Y; Zhang BH; Wu W; Qiu S; Ren ZG
Gene; 2017 Jan; 596():53-88. PubMed ID: 27729273
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of clusterin immunostaining in hepatocellular carcinoma.
Li Y; Liu F; Zhou W; Zhang S; Chu P; Lin F; Wang HL
Diagn Pathol; 2020 Oct; 15(1):127. PubMed ID: 33054843
[TBL] [Abstract][Full Text] [Related]
16. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
17. High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome.
Artemaki PI; Sklirou AD; Kontos CK; Liosi AA; Gianniou DD; Papadopoulos IN; Trougakos IP; Scorilas A
Clin Biochem; 2020 Jan; 75():62-69. PubMed ID: 31672651
[TBL] [Abstract][Full Text] [Related]
18. Impaired gap junctions in human hepatocellular carcinoma limit intrinsic oxaliplatin chemosensitivity: A key role of connexin 26.
Yang Y; Zhu J; Zhang N; Zhao Y; Li WY; Zhao FY; Ou YR; Qin SK; Wu Q
Int J Oncol; 2016 Feb; 48(2):703-13. PubMed ID: 26648344
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of GFRα1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy.
Zhu H; Huang M; Luo J; Ji X; Liu Q
Pharmacol Res; 2021 Oct; 172():105815. PubMed ID: 34391932
[TBL] [Abstract][Full Text] [Related]
20. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy.
Fu N; Du H; Li D; Lu Y; Li W; Wang Y; Kong L; Du J; Zhao S; Ren W; Han F; Wang R; Zhang Y; Nan Y
Life Sci; 2020 Sep; 256():117911. PubMed ID: 32504756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
